The Role of IL33/ST2 Axis in ARDS Patients

The main objective is the study of the role of IL33/ST2 axis in the pathogenesis of ARDS, it´s value as prognosis marker and as therapeutic target.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Respiratory Distress Syndrome Lung Diseases Respiration Disorders Respiratory Distress Syndrome Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitary Vall d´Hebron

Barcelona, 08035, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

ARDS
Risk pathologies to develop ARDS (sepsis, pancreatitis, pneumonia, massive transfussion, politraumatics)

Exclusion criteria

Age under 18
Pregnancy
Undergoing a clinical trial

Treatment and study plan

Primary outcomes

Prognostic value of the IL-33/ST2 axis in patients with ARDS.

Time frame: 60 days

Secondary outcomes

Value of IL33/ST2 axis to predict development of ARDS in risk patients

Time frame: 60 days

Sponsors and collaborators

Lead sponsor

Hospital Universitari Vall d'Hebron Research Institute

Other

Registry information

Important dates

Study start: 2015
Primary completion: 2015
Study completion: 2019
First posted: Jul 8, 2015
Registry last updated: Feb 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed